MDGL — Madrigal Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $7.22bn
- $6.41bn
- $180.13m
- 63
- 7
- 100
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.56 | ||
| Price to Tang. Book | 9.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 40.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.03% | ||
| Return on Equity | -80.35% | ||
| Operating Margin | -276.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 180.13 | 584.01 | 1,020.56 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Directors
- Paul Friedman CHM (78)
- Alex Howarth CFO (52)
- Rebecca Taub CEX (69)
- Brian Lynch SVP (59)
- Dominic Labriola SVP
- Remy Sukhija SVP (49)
- Frederick Craves LED (75)
- Kenneth Bate IND (70)
- James Daly IND (59)
- Keith Gollust IND (75)
- Richard Levy IND (63)
- David Milligan IND (80)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 10th, 2000
- Public Since
- February 6th, 2007
- No. of Shareholders
- 23
- No. of Employees
- 528
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 22,080,246
- Address
- 200 Barr Harbor Dr Ste 400, WEST CONSHOHOCKEN, 19428-2978
- Web
- https://www.madrigalpharma.com/
- Phone
- +1 4043809263
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for MDGL
Q1 2025 Madrigal Pharmaceuticals Inc Earnings Release
Madrigal Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Madrigal Pharmaceuticals Inc Earnings Release
Similar to MDGL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Madrigal Pharmaceuticals share price?
As of Today at 21:51 UTC, shares in Madrigal Pharmaceuticals are trading at $326.79. This share price information is delayed by 15 minutes.
How has the Madrigal Pharmaceuticals share price performed this year?
Shares in Madrigal Pharmaceuticals last closed at $326.79 and the price had moved by +68.12% over the past 365 days. In terms of relative price strength the Madrigal Pharmaceuticals share price has outperformed the S&P500 Index by +55.18% over the past year.
What are the analyst and broker recommendations for Madrigal Pharmaceuticals?
The overall consensus recommendation for Madrigal Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Madrigal Pharmaceuticals dividend yield?
Madrigal Pharmaceuticals does not currently pay a dividend.
Does Madrigal Pharmaceuticals pay a dividend?
Madrigal Pharmaceuticals does not currently pay a dividend.
When does Madrigal Pharmaceuticals next pay dividends?
Madrigal Pharmaceuticals does not currently pay a dividend.
How do I buy Madrigal Pharmaceuticals shares?
To buy shares in Madrigal Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Madrigal Pharmaceuticals?
As of the previous close price of $326.79, shares in Madrigal Pharmaceuticals had a market capitalisation of $7.22bn.
Where are Madrigal Pharmaceuticals shares listed?
Here are the trading details for Madrigal Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MDGL
What kind of share is Madrigal Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Madrigal Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Madrigal Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Madrigal Pharmaceuticals is $414.07. That is 26.71% above the last closing price of $326.79.
Analysts covering Madrigal Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$12.86 for the next financial year.
Find out moreWhat is the trend in the Madrigal Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Madrigal Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +63.49%.
As of the last closing price of $326.79, shares in Madrigal Pharmaceuticals were trading +12.56% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Madrigal Pharmaceuticals PE Ratio?
The Madrigal Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $326.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' management team is headed by:
- Paul Friedman - CHM
- Alex Howarth - CFO
- Rebecca Taub - CEX
- Brian Lynch - SVP
- Dominic Labriola - SVP
- Remy Sukhija - SVP
- Frederick Craves - LED
- Kenneth Bate - IND
- James Daly - IND
- Keith Gollust - IND
- Richard Levy - IND
- David Milligan - IND